Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease

Author： Small G.  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.17, Iss.12, 2003-01, pp. : 905-914

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Galantamine is beneficial in both patients with vascular dementia and patients with Alzheimer's disease with cerebrovascular disease

By  

Inpharma, Vol. 1, Iss. 1409, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Assessing the Health and Economic Impact of Galantamine Treatment in Patients with Alzheimer’s Disease in the Health Care Systems of Different Countries

By Jaime Caro   Maribel Salas  

Drugs & Aging, Vol. 21, Iss. 10, 2004-01 ,pp. : 677-686

Adis International

Access to resources Recommend Favorite

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease

By Wilcock G.  

Drugs & Aging, Vol. 20, Iss. 10, 2003-01 ,pp. : 777-789

Adis International

Access to resources Recommend Favorite

Current status and new developments with galantamine in the treatment of Alzheimer’s disease

By Tariot Pierre  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 12, 2001-12 ,pp. : 2027-2049

Informa Healthcare

Access to resources Recommend Favorite

Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer’s disease

By Marco-Contelles José   Rodríguez Carolina   García Antonio G  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 5, 2005-05 ,pp. : 575-587

Informa Healthcare

Access to resources Recommend Favorite